These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3800492)

  • 1. Pharmacokinetics and pharmacodynamics of furosemide in geriatric patients.
    Mühlberg W; Platt D; Neubig E
    Arch Gerontol Geriatr; 1986 Oct; 5(3):249-63. PubMed ID: 3800492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Furosemide--pharmacokinetics in geriatric patients with multimorbidity].
    Neubig E; Mühlberg W; Platt D
    Z Gerontol; 1984; 17(5):251-60. PubMed ID: 6523981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent pharmacokinetics of furosemide in the rat.
    Hammarlund MM; Paalzow LK
    Biopharm Drug Dispos; 1982; 3(4):345-59. PubMed ID: 7159689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and urinary kinetics of furosemide in newborn infants.
    Tuck S; Morselli P; Broquaire M; Vert P
    J Pediatr; 1983 Sep; 103(3):481-5. PubMed ID: 6886918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Furosemide effects in patients with chronic renal insufficiency].
    Sperschneider H; Stein G; Traeger A; Keil E
    Z Gesamte Inn Med; 1984 Jun; 39(11):261-5. PubMed ID: 6475170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary evaluation of furosemide-probenecid interaction in humans.
    Smith DE; Gee WL; Brater DC; Lin ET; Benet LZ
    J Pharm Sci; 1980 May; 69(5):571-5. PubMed ID: 7381747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic disposition and protein binding of furosemide in newborn infants.
    Aranda JV; Perez J; Sitar DS; Collinage J; Portuguez-Malavasi A; Duffy B; Dupont C
    J Pediatr; 1978 Sep; 93(3):507-11. PubMed ID: 690779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog.
    Hirai J; Miyazaki H; Taneike T
    J Vet Pharmacol Ther; 1992 Sep; 15(3):231-9. PubMed ID: 1433485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in derived parameters of furosemide pharmacokinetics.
    Chennavasin P; Johnson RA; Brater DC
    J Pharmacokinet Biopharm; 1981 Oct; 9(5):623-33. PubMed ID: 7334462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study.
    Silbert BI; Ho KM; Lipman J; Roberts JA; Corcoran TB; Morgan DJ; Pavey W; Mas E; Barden AE; Mori TA
    Crit Care Med; 2016 Oct; 44(10):e923-9. PubMed ID: 27183025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.
    Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and diuretic effect of furosemide in the nephrotic syndrome.
    Keller E; Hoppe-Seyler G; Schollmeyer P
    Clin Pharmacol Ther; 1982 Oct; 32(4):442-9. PubMed ID: 7116760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.